The Food and Drug Administration has approved Eohilia, a budesonide oral suspension, for 12 weeks of treatment in adults and adolescents age 11 and older with eosinophilic esophagitis, creating the first FDA-approved oral therapy specifically indicated for the chronic inflammatory disease. The agency’s newly approved prescribing information lists a dose of 2 milligrams twice daily and limits the indicated treatment course to 12 weeks.

Eosinophilic esophagitis, or EoE, is an immune-mediated disorder in which eosinophils accumulate in the esophagus, producing inflammation that can cause difficulty swallowing, pain and food impaction. The condition has historically been managed with diet changes, acid-suppressing drugs and swallowed corticosteroids used off label. Dupilumab became the first FDA-approved drug specifically for EoE in 2022, but it is an injectable biologic. Eohilia gives clinicians an approved oral option formulated to coat the esophagus.

A formulation designed for local delivery

Eohilia contains budesonide, a corticosteroid already used in other inflammatory diseases, but the oral suspension is designed for esophageal exposure. The FDA label instructs patients to shake the single-dose stick pack before use, swallow the suspension and avoid food or drink for 30 minutes afterward. The goal is to maximize contact between the medication and the inflamed esophageal lining.

The product emerged from a long clinical-development program previously known as TAK-721 or budesonide oral suspension. Takeda said in a September 2023 update that FDA had accepted a resubmitted New Drug Application focused on short-term treatment after the company revised its proposed indication and reanalyzed clinical data following earlier regulatory feedback.

The approval therefore reflects a narrower treatment claim than developers initially pursued. The label states that safety and effectiveness beyond 12 weeks have not been established, an important limitation for a disease that is chronic and often requires long-term management.

Phase 3 trial shows 53.1% histologic response

The pivotal evidence includes a randomized Phase 3 trial in 318 patients with EoE and dysphagia. In the published trial, 213 patients received budesonide oral suspension and 105 received placebo. After 12 weeks, 53.1% of treated patients achieved the stringent histologic endpoint of no more than six eosinophils per high-power field, compared with 1.0% of placebo patients.

The same study found a dysphagia symptom response in 52.6% of treated patients versus 39.1% receiving placebo and significantly greater improvement in Dysphagia Symptom Questionnaire scores. Endoscopic measures also improved more with budesonide. The ClinicalTrials.gov record describes the study as a randomized, double-blind, placebo-controlled trial in patients age 11 to 55, with histologic and symptom-response endpoints.

Adolescent-specific evidence is also important because the new indication begins at age 11. A 2023 pooled analysis of Phase 2 and Phase 3 data included 76 adolescents. Histologic response at the stringent six-eosinophil threshold occurred in 46.7% of adolescents receiving budesonide oral suspension compared with 6.5% receiving placebo, while a combined clinicopathologic response occurred in 31.1% versus 3.2%.

Long-term disease still requires a management strategy

EoE is not generally a 12-week illness. It is a chronic condition in which inflammation can recur after treatment ends, raising questions about how Eohilia will fit into maintenance care. A long-term extension study examined patients who continued or withdrew budesonide after initial treatment. Among initial full responders, relapse occurred numerically less often among those who continued therapy than among those switched to placebo, although the study’s primary comparison was not statistically significant.

That longer-duration experience helps explain both the clinical interest in ongoing anti-inflammatory treatment and the caution in the approved indication. FDA has authorized 12 weeks, so clinicians must distinguish between evidence generated in longer studies and the treatment duration actually supported by the current label.

Safety considerations are also consistent with corticosteroid therapy. The label warns about hypercorticism and adrenal-axis suppression, increased susceptibility to infection, fungal infections of the mouth and esophagus, and other systemic corticosteroid effects. Because budesonide is metabolized through CYP3A4, the label also warns about interactions that can increase drug exposure and instructs patients to avoid grapefruit juice.

A second approved drug expands EoE treatment choices

The EoE treatment landscape changed substantially when dupilumab received FDA approval in 2022. Sanofi and Regeneron’s approval announcement reported that the injectable biologic produced histologic remission in roughly 60% of treated patients in its Phase 3 program and significantly improved dysphagia symptoms. That approval established the first drug specifically indicated for EoE.

Eohilia addresses the disease through a different mechanism and route. Rather than systemically targeting interleukin signaling with a biologic injection, it delivers a corticosteroid orally to suppress inflammation at the esophageal surface. The distinction gives patients and clinicians choices that can reflect disease severity, age, preference, prior response, insurance coverage and willingness to use an injectable treatment.

The approval also formalizes a treatment approach that gastroenterologists have used for years in improvised forms, such as swallowing asthma steroid preparations rather than inhaling them. A standardized, FDA-reviewed formulation may simplify dosing and provide clearer safety and efficacy information, even though cost and coverage will determine how accessible the new product becomes.

For patients, the central finding is straightforward: a disease once managed entirely through diets, acid suppression and off-label therapies now has two FDA-approved drug classes, including its first approved oral option. The unresolved question is how physicians will sequence those therapies and maintain disease control after Eohilia’s 12-week labeled course ends.